Administration of the Interleukin-1 Inhibitor Canakinumab in Children with Autoinflammatory Diseases and Systemic Juvenile Arthritis: the Report for Case Series
In Russia, the interleukin-1 inhibitor canakinumab (fully human monoclonal antibodies to interleukin-1) is increasingly used for treating autoinflammatory diseases and systemic juvenile arthritis (sJIA). The article describes the experience of administering canakinumab in patients with autoinflammat...
Main Authors: | S. O. Salugina, M. I. Kaleda, Ye. S. Fyodorov, I. P. Nikishina |
---|---|
Format: | Article |
Language: | English |
Published: |
"Paediatrician" Publishers LLC
2016-02-01
|
Series: | Вопросы современной педиатрии |
Subjects: | |
Online Access: | https://vsp.spr-journal.ru/jour/article/view/1586 |
Similar Items
-
Results of molecular genetic screening of mutations in the NLRP3, TNFRSF1A, and MVK genes in patients with autoinflammatory diseases and systemic juvenile arthritis
by: S. O. Salugina, et al.
Published: (2017-09-01) -
A familial case of Muckle-Wells syndrome in a Russian population: The first successes of therapy with the interleukin 1 inhibitor canakinumab
by: S. O. Salugina, et al.
Published: (2015-03-01) -
The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
by: Svetlana Olegovna Salugina, et al.
Published: (2014-12-01) -
Biological disease-modifying antirheumatic drugs in the main monogenic autoinflammatory diseases treatment. Experience of application in rheumatological practice
by: S. O. Salugina, et al.
Published: (2021-08-01) -
CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
by: Ye. I. Alekseeva, et al.
Published: (2014-12-01)